Naloxone Access: Answering Questions

A Virtual Public Meeting

What: The Reagan-Udall Foundation for the FDA (FDA Foundation), in collaboration with the U.S. Food and Drug Administration, is hosting a virtual public meeting to explore questions about access to naloxone, a drug used to reverse opioid overdoses. Harm reduction specialists, physicians, pharmacists, and regulators will share their experiences in addressing the availability of this life-saving medication for heroin, fentanyl, and prescription opioid overdose. Significant time is set aside to allow public comment for up to 30 people (pre-registration required). See the FDA press release for more information. 

When: March 29, 2022; 12:30-3 PM Eastern 

Why: The FDA Foundation and FDA want to help answer some of the most frequently asked questions about access to naloxone and hear from individuals, practitioners, advocates, and others about their experiences with naloxone access 

Who should attend: Pharmacists, physicians, and other healthcare providers; harm reduction, substance use disorder, and behavioral health specialists; public health officials and community leaders; patient advocates and individuals with lived experience; industry, and others with an interest in learning more about naloxone. This meeting is open to the public. 

Contact: Visit the FDA Foundation website for more information and to register. Media inquiries can be addressed to Lea Ann Browning-McNee (; 301.509.1846).  

About the Reagan-Udall Foundation for the FDA

The Reagan-Udall Foundation for the FDA (FDA Foundation) is an independent 501(c)(3) created by Congress to advance regulatory science to help the U.S. Food and Drug Administration accomplish its mission. The FDA Foundation works to improve health and safety through stakeholder engagement and public-private partnerships that facilitate innovation, foster the use of real-world evidence, and identify modern tools and policies to keep pace with today’s rapidly evolving science.

Media Contacts:

Lea Ann Browning-McNee
301-509-1846 (cell)